Literature DB >> 25232454

Circulating microRNAs in patients with non-alcoholic fatty liver disease.

Mehmet Celikbilek1, Mevlut Baskol1, Serpil Taheri1, Kemal Deniz1, Serkan Dogan1, Gokmen Zararsiz1, Sebnem Gursoy1, Kadri Guven1, Omer Ozbakır1, Munis Dundar1, Mehmet Yucesoy1.   

Abstract

AIM: To identify novel non-invasive biomarkers for non-alcoholic fatty liver disease (NAFLD).
METHODS: Twenty patients with histologically proven NAFLD and 20 controls were included. All NAFLD cases were scored using the NAFLD activity score. The relative expressions of miR-197, miR-146b, miR-10b, miR-181d, miR-34a, miR-122, miR-99a and miR-29a were analyzed using real-time polymerase chain reaction.
RESULTS: Serum levels of miR-181d, miR-99a, miR-197 and miR-146b were significantly lower in biopsy-proven NAFLD patients than in the healthy controls. Serum levels of miR-197 and miR-10b were inversely correlated with degree of inflammation and miR-181d and miR-99a were inversely correlated with serum gamma glutamyl transferase levels in non-alcoholic steatohepatitis patients.
CONCLUSION: NAFLD is associated with altered serum miRNA expression pattern. This study provides clues for defining the non-invasive diagnosis of NAFLD.

Entities:  

Keywords:  MicroRNA; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Noninvasive; Serum markers

Year:  2014        PMID: 25232454      PMCID: PMC4163744          DOI: 10.4254/wjh.v6.i8.613

Source DB:  PubMed          Journal:  World J Hepatol


  22 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Identification of MicroRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening.

Authors:  Ross Whittaker; Patricia A Loy; Eugene Sisman; Eigo Suyama; Pedro Aza-Blanc; Randall S Ingermanson; Jeffrey H Price; Patrick M McDonough
Journal:  J Biomol Screen       Date:  2010-07-16

Review 3.  MicroRNAs and beyond: the heart reveals its treasures.

Authors:  Blanche Schroen; Stephane Heymans
Journal:  Hypertension       Date:  2009-10-19       Impact factor: 10.190

4.  Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?

Authors:  Yusuf Yilmaz
Journal:  World J Hepatol       Date:  2012-12-27

5.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

6.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

7.  Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes.

Authors:  M Balasubramanyam; S Aravind; K Gokulakrishnan; P Prabu; C Sathishkumar; H Ranjani; V Mohan
Journal:  Mol Cell Biochem       Date:  2011-01-20       Impact factor: 3.396

8.  Differential expression of microRNAs in mouse liver under aberrant energy metabolic status.

Authors:  Shengjie Li; Xi Chen; Hongjie Zhang; Xiangying Liang; Yang Xiang; Chaohui Yu; Ke Zen; Youming Li; Chen-Yu Zhang
Journal:  J Lipid Res       Date:  2009-04-16       Impact factor: 5.922

9.  MicroRNAs in Vascular Biology.

Authors:  Munekazu Yamakuchi
Journal:  Int J Vasc Med       Date:  2012-09-26

10.  Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Silvia Cermelli; Anna Ruggieri; Jorge A Marrero; George N Ioannou; Laura Beretta
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

View more
  35 in total

1.  Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study.

Authors:  Amir Zarrinpar; Shakti Gupta; Mano R Maurya; Shankar Subramaniam; Rohit Loomba
Journal:  Gut       Date:  2015-05-22       Impact factor: 23.059

2.  A micro-RNA expression signature for human NAFLD progression.

Authors:  Yan Guo; Yanhua Xiong; Quanghu Sheng; Shilin Zhao; Julia Wattacheril; Charles Robb Flynn
Journal:  J Gastroenterol       Date:  2016-02-13       Impact factor: 7.527

Review 3.  Epigenetic Aspects and Prospects in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 4.  Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?

Authors:  Peter Willeit; Philipp Skroblin; Stefan Kiechl; Carlos Fernández-Hernando; Manuel Mayr
Journal:  Eur Heart J       Date:  2016-04-20       Impact factor: 29.983

Review 5.  miRNAs in non-alcoholic fatty liver disease.

Authors:  Zhen He; Cheng Hu; Weiping Jia
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

6.  Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.

Authors:  Rocío Gallego-Durán; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-10-28

Review 7.  Circulating microRNAs in nonalcoholic fatty liver disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-15       Impact factor: 3.869

8.  Maternal supplementation with fish oil modulates inflammation-related MicroRNAs and genes in suckling lambs.

Authors:  Arash Veshkini; Abdollah Mohammadi-Sangcheshmeh; Ali A Alamouti; Fatemeh Kouhkan; Abdolreza Salehi
Journal:  Trop Anim Health Prod       Date:  2019-12-09       Impact factor: 1.559

9.  The Circulating Micro-RNAs (-122, -34a and -99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases.

Authors:  Olfat M Hendy; Hatem Rabie; Amr El Fouly; Mohamed Abdel-Samiee; Nashwa Abdelmotelb; Amr Aly Elshormilisy; Mahmoud Allam; Samia Taher Ali; Nessren Mohamed Bahaa El-Deen; Shimaa Abdelsattar; Somia Mokabel Mohamed
Journal:  Diabetes Metab Syndr Obes       Date:  2019-12-19       Impact factor: 3.168

10.  Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.

Authors:  Xiaofang Zhang; Eralda Asllanaj; Masoud Amiri; Eliana Portilla-Fernandez; Wichor M Bramer; Jana Nano; Trudy Voortman; Qiuwei Pan; Mohsen Ghanbari
Journal:  Eur J Clin Invest       Date:  2021-01-04       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.